Vanda Pharmaceuticals Inc. announces FDA approval of NEREUS™ (tradipitant) for the prevention of vomiting induced by motion sickness.
This approval marks a historic milestone, introducing the first new pharmacologic treatment in motion sickness in over four decades.
NEREUS™'s efficacy is supported by robust data from three pivotal clinical trials, showcasing significant reductions in vomiting rates.
Groundbreaking Approval
FDA approval of NEREUS™ marks a significant advancement, providing a novel therapy for motion sickness after four decades.
Clinical Trial Success
NEREUS™ demonstrated impressive risk reductions in vomiting rates, highlighting its effectiveness and safety profile in motion sickness prevention.
Military Significance
Recognition of motion sickness's impact on military readiness from historical events to present day emphasizes the importance of effective treatments like NEREUS™.
- Motion sickness affects a substantial portion of the population, impacting military personnel and civilians during travel modes like cars, planes, and boats.
- NEREUS™'s mechanism of action addresses the sensory conflict triggering nausea and vomiting, offering a targeted approach in managing motion sickness symptoms.
The FDA approval of NEREUS™ represents a breakthrough in motion sickness treatment, providing hope for millions suffering from this debilitating condition. Vanda Pharmaceuticals' dedication to advancing healthcare solutions underscores their commitment to improving patient outcomes.